Alisertib-Taxol Combo Shows Promise in Recurrent Ovarian Cancer

Alisertib-Taxol Combo Shows Promise in Recurrent Ovarian Cancer
A combination of the investigational treatment alisertib and weekly Taxol (paclitaxel) showed promising anti-tumor activity in ovarian cancer patients treated in a Phase 1/2 trial, warranting further studies of the combination. The study, "Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial," was published in JAMA Oncology. Alisertib is an oral inhibitor of the aurora kinase A, a protein involved in cell division that is often overproduced in ovarian and breast cancers and linked with poor prognosis. In preclinical and Phase 1 studies, the treatment has shown potent anti-tumor activity with a manageable safety profile. Taxol is a chemotherapy agent approved for several solid tumors, and is currently the standard of care for ovarian cancer patients who have failed platinum-based chemotherapies. But while the treatment is usually given in a three-week schedule, studies suggest that a weekly administration could improve patients' outcomes. Thus, researchers aimed to test a combination of alisertib and weekly Taxol in patients with advanced breast cancer and recurrent ovarian cancer. The Phase 1/2 trial (NCT01091428) included
Subscribe or to access all post and page content.